Myocardial protective effects of the phosphodiesterase 3 inhibitor, cilostazol, in streptozotocin-induced diabetic rats were investigated. Four weeks after induction of diabetes, we measured thrombospondin-1 (TSP-1) expression in the left ventricular myocardium. Microstructural and ultrastructural changes were also analysed. Four weeks after the induction of diabetes there were significant differences in body weight and blood glucose between the control, diabetic and cilostazol-treated diabetic animals. TSP-1 expression was significantly increased in the myocardium of diabetic rats compared with the control group. Although significantly higher than the control group, TSP-1 expression was significantly lower in the cilostazol group compared with the diabetes group. There were obvious ultrastructural changes in the myocardium of diabetic rats, which were rarely seen in cilostazol-treated diabetic rats. In conclusion, this study provides experimental evidence that cilostazol treatment of diabetic rats effectively prevents pathological myocardial alterations, possibly via the down-regulation of TSP-1 expression.
Introduction
As diabetes becomes a worldwide epidemic, more and more diabetic patients face the problems of morbidity and mortality due to chronic complications. 1 -5 Diabetic cardiomyopathy is increasingly being recognized as a cause of morbidity and mortality in patients with diabetes. 6 Several mechanisms have been proposed including small-and micro-vascular disease, autonomic dysfunction, metabolic derangement, and accumulation of glycoprotein and collagen. 7 Current evidence, however, suggests that tumour necrosis factor-α (TNF-α) antagonism attenuates the development of experimental diabetic cardiomyopathy associated with a reduction in intramyocardial inflammation and cardiac fibrosis. 8 Thrombospondin-1 (TSP-1) is a matricellular, calcium-binding protein that participates in cellular responses to growth 
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factors, cytokines and injury. 9 It has previously been demonstrated that upregulation of TSP-1 expression in the diabetic rodent heart may play a role in the development of diabetic cardiomyopathy. 10 Cilostazol is a potent phosphodiesterase 3 (PDE3) inhibitor currently used in clinical practice to treat patients with peripheral arterial disease and that has been shown, in diabetic rats, to protect them from vascular inflammation. 11, 12 Research has shown that cilostazol inhibits protein kinase C (PKC) activity at the phosphoinositide 3 (PI-3) kinase level to suppress reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation in the presence of phorbol 12-myristate 13acetate (PMA) or tumour necrosis factor (TNF)-α 13 . Therefore, PDE3 inhibitors might not only suppress platelet aggregation, hinder vascular smooth muscle cell proliferation and induce vasodilatation through PKA activation, they might also suppress acceleration of oxidative stress by controlling the PI-3 kinase-dependent pathway of PKC, which is activated in the diabetic state. 13 In the present study, we induced diabetic cardiomyopathy in rats using streptozotocin (STZ) because this is the most widely used agent for producing both diabetes mellitus and its associated complications in experimental animals. 4, 14, 15 Furthermore, rats are relatively resistant to atherosclerosis and, thus, the alteration in cardiac function following STZ treatment is believed to be due to cardiomyopathy. 16 The aims of this study were: (i) to investigate the myocardial protective effects of cilostazol in experimental diabetic cardiomyopathy; and (ii) to determine the relationship between decreased TSP-1 expression in the heart and the protective effects of cilostazol on diabetic cardiomyopathy. 
Materials and methods

MATERIALS
ANIMAL MODEL INDUCTION
Forty-five 75 -90-day old male Sprague-Dawley rats with a body weight of approximately 210 g were used for this study and randomly divided into three groups (15 rats/group). The rats were housed in an environmentally-controlled animal laboratory and maintained on a 12 h light/12 h dark cycle, five rats/cage, at J Ma, M Zheng, Y Shen et al.
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ambient temperature (22 -25°C) with 55 ± 10% relative humidity.
Blood samples were taken from the caudal vein after anaesthetization. Blood glucose was measured with the glucose electrode calibrator, model QA2583-3364. Thirty rats were fasted for 12 h before 60 mg/kg STZ (lot L11655) was injected intraperitoneally to induce diabetes. The remaining 15 rats formed the control group; they were also fasted for 12 h and then received an injection of 0.9% saline.
If, 48 h after injection of STZ, blood glucose was > 16 mmol/l, this indicated successful induction of diabetes. Fifteen diabetic rats were intragastrically administered 18 mg/kg per day cilostazol for 4 weeks (cilostazol treatment group). The remaining 15 diabetic rats (the diabetes group) and the 15 control rats were given the same volume of 0.9% saline for 4 weeks by intragastric administration. Body weight and blood glucose levels were measured weekly in the three groups.
All procedures were conducted with the approval of the Zhejiang University Animal Care Committee. Ethical permission for this study was granted by the Ethical Committee of the School of Medicine, Zhejiang University (Hangzhou, China).
REAL-TIME RT-QPCR OF TSP-1
At the end of the study (4 weeks), five animals/group were anaesthetized with a lethal dose of pentobarbital. After intracardial perfusion with 100 ml of normal saline, the heart of each rat was immediately removed to obtain fresh tissue specimens. For real time RT-qPCR analysis, total RNA was isolated from the left ventricle using the TRIzol ® reagent kit according to the manufacturer's instructions. The RNA concentration was measured spectrophotometrically and 2 µg of total RNA was added to the complementary DNA synthesis reaction system (20 µl). The reaction mixture comprised 4 µl of 5 × RT buffer, 2.5 µmol/l oligodeoxythymidylic acid (oligo dT), 5 mmol/l deoxyribonucleotide triphosphate (dNTP) and 20 U of RNase inhibitor. The hexamers were annealed by incubating the samples to 70°C for 5 min. M-MLV reverse transcriptase (200 U) was added and the mixture was incubated at 42°C for 60 min. The reaction was stopped by heating to 72°C for 10 min. For real time RT-qPCR, the reaction mixture (40 µl) consisted of 4 µl complementary DNA, 35.2 µl SYBR ® Green qPCR mix, 0.5 µl of 5 U Taq DNA polymerase and 0.3 µl of 20 pmol/µl TSP-1 primer. The complementary DNA was denatured by heating to 94°C for 3 min. The template was amplified by 40 rounds of PCR (denaturation at 94°C for 10 s, annealing at 57°C for 30 s, extension at 72°C for 30 s) before collecting the fluorescence at 72°C. Meanwhile, primers were used for the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the real time RT-qPCR to amplify GAPDH as an internal control for quantifying TSP-1 expression. The primers for TSP-1 were as follows: forward, GAGTGTCACTGCCAGAACTCA 5′ -3′; and reverse, GTCTGTACTGAAGAGCCCTCA 5′ -3′. The PCR product length of TSP-1 was 248 base pairs (bp).
The RT-qPCR data were analysed by the comparative C T method in which ∆C T was determined by subtracting the mean GAPDH C T value from the mean TSP-1 C T value. Calculation of ∆∆C T for the diabetic or cilostazol treatment group was obtained by subtracting the ∆C T value for the diabetes or cilostazol treatment group, respectively, from the ∆C T control calibrator value. The TSP-1 mRNA levels in the diabetes and cilostazol treatment groups relative to control were determined from the formula: 2 -(∆∆CT) .
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IMMUNOHISTOCHEMISTRY AND HAEMATOXYLIN AND EOSIN STAINING
Immunohistochemistry was used to localize the TSP-1 antigen. A further five rats from each group were anaesthetized with a lethal dose of pentobarbital. Their thoracic cavities were then opened and perfused intracardially with normal saline. Following saline perfusion, the animals were perfused with 300 -400 ml of fixative containing 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). After perfusion, the heart of each rat was removed, fixed in the same fixative for 4 h and then placed in 30% phosphate-buffered sucrose until the tissue sank. Tissue sections (8 µm) were cut on a freezing microtome through the coronary planes of the heart. Sections were then rinsed in 0.01 M phosphate-buffered saline (PBS) pH 7.4, and mounted onto 0.02% poly-Llysine-coated slides.
The avidin-biotin-peroxidase complex technique 17 was used with 3,3′-diaminobenzidine hydrochloride (DAB) as the chromogen. Briefly, tissue sections were washed in PBS, incubated in 1% bovine serum albumin (BSA) for 30 min, and then incubated overnight at 4°C in the primary antibody (monoclonal TSP-1 antibody) plus 1% BSA in PBS. The dilution of the primary antibody was 1:100. Control sections were incubated in PBS alone. The next day, the sections were incubated in a biotinylated goat anti-mouse secondary antibody (diluted to 1:200 in PBS), and subsequently in an avidin-horseradish peroxidase solution. Immunolabelling was visualized with 0.05% DAB (Sigma, St Louis, MO, USA) plus 0.3% H 2 O 2 in PBS. The sections were then dehydrated through ethanol and xylene before being cover slipped with Permount™ (Sigma). Haematoxylin and eosin staining was also applied to determine morphological changes.
TRANSMISSION ELECTRON MICROSCOPY
Four weeks after the injection of STZ, two animals/group were anaesthetized with a lethal dose of pentobarbital. Their thoracic cavities were opened, perfused intracardially with 100 ml normal saline and the heart of each rat was removed immediately. Immersion fixation was completed on tissue from the distal left ventricle myocardium. Samples were rinsed in cold PBS (0.01 M, pH 7.4) and placed in 2.5% glutaraldehyde at 4°C for 4 h. The tissue was rinsed in buffer (0.01 M PBS, pH 7.4) and post-fixed with 1% osmium tetroxide for 1 h. It was then rinsed with distilled water before undergoing a graded ethanol dehydration series and was infiltrated using a mixture of one-half propylene oxide and one-half resin overnight. Twenty-four hours later, the tissue was embedded in resin. Tissue sections (120 nm) were cut and stained with 4% uranyl acetate for 20 min and 0.5% lead citrate for 5 min.
HAEMODYNAMIC PARAMETERS
The remaining three rats/group were tested for haemodynamic parameters. After stunning and cervical dislocation, the hearts were immediately excised and mounted on a Langendorff apparatus for perfusion at 37°C with Krebs-Henseleit (K-H) buffer at a constant pressure (76 mmHg). The left atrium was opened and a fluid-filled latex balloon was inserted into the left ventricle. The balloon was connected via a short plastic tube to a pressure transducer and computer. The hearts were perfused for approximately 30 min. Haemodynamic parameters (rate-pressure product, RPP) were monitored.
IMAGE ANALYSIS
For immunohistochemistry, the left ventricular tissues were selected on each slide J Ma, M Zheng, Y Shen et al.
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and examined at a magnification of ×400 with a UTHSCSA Image Tool 3.0 (University of Texas Medical School at San Antonio, San Antonio, TX, USA). The number and optical density of the TSP-1 positive cells were measured.
STATISTICAL ANALYSIS
All data are mean ± SD. Statistical analysis was performed using SPSS ® for Windows ® version 10.0 statistical software (SPSS Inc., Chicago, IL, USA). The significance of any differences between the groups was evaluated using the t-test. P-values were two tailed and P < 0.05 was considered as significant.
Results
BODY WEIGHT AND BLOOD GLUCOSE LEVELS
Body weight and blood glucose levels showed no significant differences among the three groups of rats before STZ injection. At the end of the study (4 weeks), the cilostazol treatment group had a significantly higher body weight (P < 0.01) and a lower blood glucose level (P < 0.01) compared with the diabetic group (Table 1) .
ASSESSMENT OF TSP-1 MRNA LEVELS
The real time RT-qPCR results showed that the TSP-1 mRNA level was down-regulated in the cilostazol treatment group compared with the diabetes group, as indicated by the increased ∆C T values (comparative C T method). Specifically, the TSP-1 mRNA level in the diabetes group was 2.63 times that of the control group and the cilostazol treatment group was 1.74 times that of the control group (Table 2 ). Figure 1 shows light photomicrographs of TSP-1 immunohistochemical staining of the myocardium from the three groups of rats. In heart tissues from the diabetic rats, the myocardium had undergone hypertrophy and structural rarefaction. Cells that stained positive for TSP-1 showed buff-coloured granules with DAB staining. The myocardium, extracellular matrix and the endothelial cells of the small vessels between the myocardium all showed increased TSP-1 expression when compared with the control group. We also observed that the subendothelial matrix of the Values are expressed as mean ± SD (n = 15). *P < 0.01 versus the control group; # P < 0.01 versus the diabetic group.
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myocardial small vessels was thickened and expressed TSP-1 intensively. Cilostazol-treated animals had a significantly decreased number of TSP-1 positive cells and decreased optical density of the TSP-1 immunostained myocardium compared with the diabetic rats (P < 0.01) ( Table 3 ). Figure  2 shows the results of haematoxylin and eosin staining of the myocardial tissues from rats in each group. We observed that the diabetic group had hypertrophy and interstitial fibrosis to Values are expressed as mean ± SD (n = 5). *P < 0.01 versus the control group; # P < 0.01 versus the cilostazol treatment group. 
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various degrees and the myocardium appeared hypertrophic with structural rarefaction. Cilostazol-treated rats showed less hypertrophy and interstitial fibrosis. Figure 3 shows the transmission electron micrographs of the myocardial tissues from rats in each of the three groups. Diabetes induced several visible and distinct changes in ultrastructure of the cardiomyocytes. When compared with the control group, samples from the left ventricle of the diabetic rat showed disordered myofibrils and swollen mitochondria. The cilostazol-treated rats showed fewer ultrastructural changes than the diabetic rats.
HEART ULTRASTRUCTURAL CHANGES
HAEMODYNAMIC PARAMETERS
The RPP after 30 min was significantly reduced in the diabetes group compared with the control group (P < 0.01) ( Fig. 4) . Cilostazol treatment significantly reduced the diabetes-induced decrease in RPP (P < 0.01), although the RPP was still significantly lower in the cilostazol-treated rats than in the control rats (P < 0.01).
Discussion
Diabetic cardiomyopathy is the most dangerous complication facing patients with diabetes. 10 Some factors have been considered to determine the risk of cardiovascular complications in diabetes mellitus, 7, 18 although the exact underlying mechanism remains controversial. TSP-1, 
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the best characterized of the five TSP isoforms, is a major component of platelet αgranules. 19 TSP-1 acts as an immediate early response gene, being rapidly up-regulated in response to serum and growth factors such as transforming growth factor-β (TGF-β) and platelet-derived growth factor. 20 Cell culture studies have indicated that TGF-β inhibits mitotic growth of cardiomyocytes, 21 and stimulates hypertrophic growth and fibrosis. 22, 23 Under diabetic conditions, there is increased production of TGF-β protein and an increase in TGF-β activity. 24 A PKCdependent signalling pathway is involved in the regulation of TGF-β and down-regulation of PKC could inhibit the activation of TGFβ. 25 Another recent study has confirmed that glucose-induced activation of TGF-β is dependent on PKC activity, leading to a sequential increase in TSP-1 synthesis in cultured human mesangial cells, suggesting that high glucose conditions could induce an increase in the PKC-TGF-β-TSP-1 system. 26 As a PDE3 inhibitor, it has been reported that cilostazol may act directly on human endothelial cells to inhibit the expression of adhesion molecules and neutrophil adhesion induced by high glucose levels. 27 This suggests that cilostazol inhibits PKC activity at the PI-3 kinase level to suppress NADPH oxidase activation in the presence of PMA or TNF-α. 13 The PDE3 inhibitors, therefore, may not only suppress platelet aggregation, 28 hinder vascular smooth muscle cell proliferation 29 and induce vasodilatation 30 through PKA activation, they might also suppress acceleration of oxidative stress in glomeruli by controlling the PI-3 kinase-dependent pathway of PKC, which is activated in the diabetic state, thus blocking the onset and progression of diabetic nephropathy and arteriosclerosis. 13 The results of our present study showed that short-term diabetes (4 weeks) leads to up-regulation of TSP-1 protein and mRNA expression in the myocardium, but that this could be prevented by cilostazol treatment. Expression of TSP-1 increased in the diabetic 
myocardium and it seems likely that TSP-1 plays a role, via the PKC-TGF-β-TSP-1 system and the mutual activation between TGF-β and TSP-1, in the development of diabetic cardiomyopathy. The present study suggests that cilostazol treatment might inhibit PKC activity at the PI-3 kinase level to suppress TSP-1 expression in rats with diabetes. Cilostazol treatment might, therefore, prevent myocardial changes in diabetic rats by decreasing TSP-1 expression and inhibiting TGF-β expression, thus preventing TGF-β-stimulated hypertrophic growth and fibrosis. In future research we will focus on the activators of TSP-1, such as TGF-β and PKC expression in the myocardium of diabetic rats to explore the influence of cilostazol on the PKC-TGFβ-TSP-1 system. The present study also used immunohistochemistry to determine the expression of the TSP-1 protein in the heart after 4 weeks of diabetes induction and to demonstrate the protective effect of cilostazol on the development of diabetic cardiomyopathy in experimental diabetes.
There was less structural damage to the heart in the cilostazol-treated group than in the diabetes group. We propose, therefore, that cilostazol treatment in the early stages of cardiomyopathy might prevent the appearance of subsequent clinical symptoms by reversing the functional and morphological abnormalities in the diabetic heart. In conclusion, treatment with the PDE3 inhibitor cilostazol was able to abrogate the diabetes-induced increase in TSP-1 expression in diabetic rat myocardium. The exact mechanism of action is unknown but will be the subject of further investigation.
